Premium
Proteomics of Caenorhabditis elegans over‐expressing human α ‐synuclein analyzed by fluorogenic derivatization–liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages
Author(s) -
Ichibangase Tomoko,
Saimaru Hiroshi,
Takamura Norio,
Kuwahara Tomoki,
Koyama Akihiko,
Iwatsubo Takeshi,
Imai Kazuhiro
Publication year - 2008
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.931
Subject(s) - chemistry , tandem mass spectrometry , caenorhabditis elegans , proteomics , proteome , liquid chromatography–mass spectrometry , neurodegeneration , synucleinopathies , mass spectrometry , biochemistry , microbiology and biotechnology , chromatography , biology , parkinson's disease , alpha synuclein , disease , medicine , pathology , gene
Abstract It has been known that the over‐expression of α ‐synuclein, the main protein of Lewy bodies in Parkinson's disease (PD), leads to neurodegeneration in PD models. In this study, the changes in protein expression between the transgenic over‐expressing human α ‐synuclein wild type ( α ‐synWT) and the control Caenorhabditis elegans were elucidated by fluorogenic derivatization–liquid chromatography/tandem mass spectrometry (FD‐LC‐MS/MS) proteome analysis, which is a highly selective, sensitive, repeatable and quantitative method for protein identification. Because the α ‐synuclein wild‐type worms showed moderate levels of dopamine loss without overt behavioral abnormalities, it was suggested that the changes in proteins in the α ‐synWT are related in the sequence of the formation of Lewy bodies. Among more than 400 protein peaks detected, actin and several ribosomal proteins were identified for the first time as negative markers at early PD stages. Actin was suggested to be one of the important targets in the elucidation of the etiology of neuronal diseases such as PD or other synucleinopathies. Copyright © 2007 John Wiley & Sons, Ltd.